Masayoshi Yada

3.8k total citations · 1 hit paper
45 papers, 3.1k citations indexed

About

Masayoshi Yada is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Masayoshi Yada has authored 45 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 18 papers in Hepatology and 15 papers in Oncology. Recurrent topics in Masayoshi Yada's work include Liver Disease Diagnosis and Treatment (18 papers), Ubiquitin and proteasome pathways (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Masayoshi Yada is often cited by papers focused on Liver Disease Diagnosis and Treatment (18 papers), Ubiquitin and proteasome pathways (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Masayoshi Yada collaborates with scholars based in Japan, United States and France. Masayoshi Yada's co-authors include Shigetsugu Hatakeyama, N. Ishida, Keiichi I. Nakayama, Masaki Matsumoto, Kei-ichi Nakayama, Takumi Kamura, Keiko Nakayama, Hiroyuki Imaki, Ryosuke Tsunematsu and Masaaki Nishiyama and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The EMBO Journal.

In The Last Decade

Masayoshi Yada

41 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7

2004 660 citations Masayoshi Yada, Shigetsugu Hatakeyama et al. The EMBO Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masayoshi Yada Japan	17	2.1k	863	861	446	308	45	3.1k
Nada Y. Kalaany United States	12	2.0k 0.9×	548 0.6×	659 0.8×	301 0.7×	180 0.6×	14	3.1k
Suchithra Menon United States	14	2.8k 1.3×	407 0.5×	676 0.8×	562 1.3×	215 0.7×	20	3.9k
Norman J. Kennedy United States	23	2.2k 1.0×	553 0.6×	299 0.3×	359 0.8×	146 0.5×	32	3.1k
Keren Paz United States	21	1.7k 0.8×	560 0.6×	233 0.3×	701 1.6×	148 0.5×	33	2.6k
Jessica L. Yecies United States	10	2.0k 0.9×	319 0.4×	468 0.5×	304 0.7×	202 0.7×	13	3.0k
Beixue Gao United States	31	1.5k 0.7×	382 0.4×	617 0.7×	494 1.1×	70 0.2×	42	2.6k
Olivier Geneste France	22	1.7k 0.8×	353 0.4×	894 1.0×	372 0.8×	87 0.3×	35	2.7k
Rui-Hong Wang United States	15	1.6k 0.7×	496 0.6×	869 1.0×	202 0.5×	94 0.3×	16	3.4k
Fawzia Bardag‐Gorce United States	31	1.5k 0.7×	230 0.3×	734 0.9×	745 1.7×	113 0.4×	93	2.6k
Kiki Chu United States	18	1.0k 0.5×	284 0.3×	630 0.7×	240 0.5×	301 1.0×	21	2.2k

Countries citing papers authored by Masayoshi Yada

Since Specialization

Citations

This map shows the geographic impact of Masayoshi Yada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masayoshi Yada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masayoshi Yada more than expected).

Fields of papers citing papers by Masayoshi Yada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masayoshi Yada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masayoshi Yada. The network helps show where Masayoshi Yada may publish in the future.

Co-authorship network of co-authors of Masayoshi Yada

This figure shows the co-authorship network connecting the top 25 collaborators of Masayoshi Yada. A scholar is included among the top collaborators of Masayoshi Yada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masayoshi Yada. Masayoshi Yada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suzuki, Hideo, et al.. (2025). Prognostic Significance of Lymphocyte-to-Monocyte Ratio in Patients With Unresectable Biliary Tract Cancer Undergoing Systemic Chemotherapy. Cancer Diagnosis & Prognosis. 5(1). 132–137. 1 indexed citations

Tanaka, Masatake, Takao Hamamoto, Hideo Suzuki, et al.. (2025). Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab. Anticancer Research. 45(12). 5697–5708.

Yada, Masayoshi, et al.. (2024). Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B. Cancer Diagnosis & Prognosis. 4(2). 111–116. 1 indexed citations

Motomura, Kenta, et al.. (2023). Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers. 15(17). 4345–4345. 6 indexed citations

Yada, Masayoshi, Yoshiko Miyazaki, Kosuke Tanaka, et al.. (2023). Tumor‑infiltrating CD8⁺ T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma. Oncology Letters. 25(6). 259–259. 14 indexed citations

Tanaka, Masatake, et al.. (2023). Combined Ultrasound and Computed Tomography Guidance in Radiofrequency Ablation for Hepatocellular Carcinoma Reduces Local Recurrence Rate. Cancer Diagnosis & Prognosis. 3(6). 660–666. 2 indexed citations

Yada, Masayoshi, Yoshiko Miyazaki, Masatake Tanaka, et al.. (2023). An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. Cancer Diagnosis & Prognosis. 3(4). 468–474. 4 indexed citations

Yada, Masayoshi, Masayuki Miyazaki, Masatake Tanaka, Akihide Masumoto, & Kenta Motomura. (2018). Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World Journal of Gastroenterology. 24(13). 1478–1485. 4 indexed citations

Miyazaki, Masayuki, Masayoshi Yada, Masatake Tanaka, et al.. (2017). Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology. 23(29). 5379–5379. 1 indexed citations

10.

Yada, Masayoshi. (2014). Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology. 20(35). 12581–12581. 31 indexed citations

11.

Masumoto, Akihide, et al.. (2013). Liver abscess due to Fusobacterium caused by dental bacterial infection: report of two cases. Kanzo. 54(5). 347–353. 1 indexed citations

12.

Nakamuta, Makoto, Ryoko Yada, Yoko Aoyagi, et al.. (2011). Expression profiles of genes associated with viral entry in HCV‐infected human liver. Journal of Medical Virology. 83(5). 921–927. 14 indexed citations

13.

Tajiri, H., et al.. (2010). A case of cirrhosis due to pravastatin-induced autoimmune hepatitis. Kanzo. 51(2). 71–77. 2 indexed citations

14.

Fujino, Tatsuya, Makoto Nakamuta, Ryoko Yada, et al.. (2010). Expression profile of lipid metabolism‐associated genes in hepatitis C virus‐infected human liver. Hepatology Research. 40(9). 923–929. 35 indexed citations

15.

Yada, Masayoshi, Shigetsugu Hatakeyama, Takumi Kamura, et al.. (2004). Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7. The EMBO Journal. 23(10). 2116–2125. 660 indexed citations breakdown →

16.

Kamura, Takumi, Taichi Hara, Shuhei Kotoshiba, et al.. (2003). Degradation of p57 ^Kip2 mediated by SCF ^Skp2 -dependent ubiquitylation. Proceedings of the National Academy of Sciences. 100(18). 10231–10236. 250 indexed citations

17.

Oshikawa, Kiyotaka, Masaki Matsumoto, Masayoshi Yada, et al.. (2003). Preferential interaction of TIP120A with Cul1 that is not modified by NEDD8 and not associated with Skp1. Biochemical and Biophysical Research Communications. 303(4). 1209–1216. 54 indexed citations

18.

Yamanaka, Atsushi, Masayoshi Yada, Hiroyuki Imaki, et al.. (2002). Multiple Skp1-Related Proteins in Caenorhabditis elegans. Current Biology. 12(4). 267–275. 63 indexed citations

19.

Hatakeyama, Shigetsugu, Masayoshi Yada, Masaki Matsumoto, N. Ishida, & Kei-ichi Nakayama. (2001). U Box Proteins as a New Family of Ubiquitin-Protein Ligases. Journal of Biological Chemistry. 276(35). 33111–33120. 471 indexed citations

20.

Sugiyama, Hironori, et al.. (1986). [A case of multiple myeloma associated with gastric cancer, rectal cancer and myelomatous pleural effusion in the terminal stage].. PubMed. 27(12). 2313–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact